NovMetaPharma Co Ltd

Capital Structure and Liquidity NovMetaPharma maintains a low debt-to-equity ratio of 0.04, indicating a conservative capital structure with minimal leverage. The company's liquidity position is assessed as low, with a current ratio of 1.83, suggesting limited short-term liquidity cushion. Cash and equivalents amount to KRW 520.6 billion, but this is offset by negative operating and free cash flows of KRW -335.8 billion and KRW -102.4 billion, respectively, signaling ongoing cash burn. ### Profitability and Returns The company is unprofitable, with a net loss of KRW -10.5 billion and an operating loss of KRW -53.7 billion in the latest period. Return on equity is -2.91, and return on assets is -2.39, both significantly below the industry norms for biotechnology and pharmaceutical firms. These metrics suggest operational inefficiencies and a lack of asset productivity. ### Segments and Geographic Exposure NovMetaPharma operates through two segments: New Drug Development and Health Functional Food. The New Drug Development segment focuses on chronic disease treatments, while the Health Functional Food segment includes products for blood sugar, prostate health, and cognitive improvement. The company distributes domestically and to the U.S. and China, but revenue concentration data is not provided in the input, so geographic exposure cannot be quantified. ### Growth Trajectory The company's recent financial performance shows a significant decline in profitability, with a net loss of KRW -10.5 billion and a revenue of KRW 34.8 billion. There are no provided outlook figures for the current or next fiscal year, so growth trajectory cannot be assessed numerically. ### Risk Factors The company faces low liquidity risk, but its negative operating and free cash flows indicate ongoing cash outflows that could pressure liquidity in the near term. Dilution risk is assessed as low, with no immediate filing-based flags detected. However, the company's negative net income and operating income suggest potential for future dilution if capital raising is required. ### Recent Events No specific recent events such as filings or transcripts are provided in the input data to inform the narrative.